Skip to content

Study · Randomized controlled trial · n = 60 · 2002

6 results

Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa.

Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A

The Journal of clinical endocrinology and metabolism1 Jun 2002Cited by 213 (Europe PMC)

PMID12050268 (opens in a new tab)DOI10.1210/jcem.87.6.8574 (opens in a new tab)PepBankPUB-12050268
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In osteopenic women with anorexia nervosa, factorial analysis showed greater spinal bone density change with rhIGF-I than placebo.

    In plain wordsIn women with anorexia nervosa, spinal bone density increased more with rhIGF-I than placebo in the factorial analysis.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseFactorial spinal bone density
    Study

    n = 60

    Comparator
    All placebo-treated subjects
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 microg/kg twice daily · subcutaneous · 9 monthsAs given in this study (human).

    Measurements

    Anteroposterior spinal bone density change, mean (+/- 0.5%)
    1.1%
    all rhIGF-I-treated subjects
    Anteroposterior spinal bone density change, mean (+/- 0.8%)
    −0.6%
    all placebo-treated subjects
    P value for spinal bone density change comparison
    0.05 P value
    all rhIGF-I versus all placebo treated, analysis of covariance

    Source sentences

    Summary
    Anteroposterior spinal bone density increased significantly in response to rhIGF-I (1.1% +/- 0.5% vs. -0.6% +/- 0.8%, P = 0.05, all rhIGF-I vs. all placebo treated, respectively, by analysis of covariance).
    2 context sentences
    Summary · context
    We tested the hypothesis that recombinant human IGF-I (rhIGF-I) would increase bone density in women with anorexia nervosa and furthermore assessed the effects of combined rhIGF-I and oral contraceptive administration (OCP) in this population.
    Summary · context
    Administration of rhIGF-I was placebo controlled and blinded to subjects.
  2. 02HumanRandomized controlled trialSafety outcome

    In women with anorexia nervosa, titrated rhIGF-I was well tolerated.

    In plain wordsIn women with anorexia nervosa, rhIGF-I was well tolerated.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    Not applicableTolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    30 microg/kg twice daily · subcutaneous · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    The rhIGF-I was titrated to maintain IGF-I levels within the age-adjusted normal range for each patient and was well tolerated.
    2 context sentences
    Summary · context
    We tested the hypothesis that recombinant human IGF-I (rhIGF-I) would increase bone density in women with anorexia nervosa and furthermore assessed the effects of combined rhIGF-I and oral contraceptive administration (OCP) in this population.
    Summary · context
    Administration of rhIGF-I was placebo controlled and blinded to subjects.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In osteopenic women with anorexia nervosa, spinal bone density changed by 0.3% +/- 0.6% with rhIGF-I alone.

    In plain wordsIn women with anorexia nervosa, spinal bone density changed by 0.3% in the rhIGF-I-alone group.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    Direction not reportedIGF-I-alone spinal bone density change
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 microg/kg twice daily · subcutaneous · 9 monthsAs given in this study (human).

    Measurements

    Spinal bone density change, mean (+/- 0.6%)
    0.3%
    rhIGF-I alone

    Source sentences

    Summary
    However, bone density increased to the greatest extent in the combined treatment group (rhIGF-I and OCP), compared with control patients receiving no active therapy (1.8% +/- 0.8% vs. 0.3% +/- 0.6% vs. -0.2% +/- 0.8% vs. -1.0% +/- 1.3%, rhIGF-I and OCP vs. rhIGF-I alone vs. OCP alone vs. no active t…
    2 context sentences
    Summary · context
    We tested the hypothesis that recombinant human IGF-I (rhIGF-I) would increase bone density in women with anorexia nervosa and furthermore assessed the effects of combined rhIGF-I and oral contraceptive administration (OCP) in this population.
    Summary · context
    Administration of rhIGF-I was placebo controlled and blinded to subjects.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In osteopenic women with anorexia nervosa, spinal bone density change was 1.8% with rhIGF-I plus OCP versus -0.2% with OCP alone.

    In plain wordsIn women with anorexia nervosa, spinal bone density change was greater with rhIGF-I plus oral contraceptive than oral contraceptive alone.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseCombined treatment spinal bone density versus OCP alone
    Study

    n: not reported in source

    Comparator
    OCP alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 microg/kg twice daily · subcutaneous · 9 monthsAs given in this study (human).

    Measurements

    Spinal bone density change, mean (+/- 0.8%)
    1.8%
    rhIGF-I plus OCP
    Spinal bone density change, mean (+/- 0.8%)
    −0.2%
    OCP alone

    Source sentences

    Summary
    However, bone density increased to the greatest extent in the combined treatment group (rhIGF-I and OCP), compared with control patients receiving no active therapy (1.8% +/- 0.8% vs. 0.3% +/- 0.6% vs. -0.2% +/- 0.8% vs. -1.0% +/- 1.3%, rhIGF-I and OCP vs. rhIGF-I alone vs. OCP alone vs. no active t…
    1 context sentence
    Summary · context
    rhIGF-I (30 microg/kg sc twice daily) and a daily oral contraceptive (Ovcon 35, 35 microg ethinyl estradiol and 0.4 mg norethindrone], rhIGF-I alone (30 microg/kg sc twice daily), oral contraceptive alone, or neither treatment for 9 months.

Studies that did not test the peptide alone2

In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 (mecasermin).

  1. 05HumanNot a test of IGF-1 (mecasermin) aloneRandomized controlled trialEfficacy outcome

    In osteopenic women with anorexia nervosa, rhIGF-I plus OCP increased spinal bone density more than no active therapy.

    In plain wordsIn women with anorexia nervosa, rhIGF-I plus oral contraceptive increased spinal bone density more than no active therapy.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseCombined treatment spinal bone density
    Study

    n: not reported in source

    Comparator
    No active therapy
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Spinal bone density change, mean (+/- 0.8%)
    1.8%
    rhIGF-I plus OCP
    Spinal bone density change, mean (+/- 1.3%)
    −1%
    no active therapy
    P value for spinal bone density change comparison
    < 0.05 P value
    rhIGF-I and OCP versus no active therapy

    Source sentences

    Summary
    However, bone density increased to the greatest extent in the combined treatment group (rhIGF-I and OCP), compared with control patients receiving no active therapy (1.8% +/- 0.8% vs. 0.3% +/- 0.6% vs. -0.2% +/- 0.8% vs. -1.0% +/- 1.3%, rhIGF-I and OCP vs. rhIGF-I alone vs. OCP alone vs. no active t…
    2 context sentences
    Summary · context
    We tested the hypothesis that recombinant human IGF-I (rhIGF-I) would increase bone density in women with anorexia nervosa and furthermore assessed the effects of combined rhIGF-I and oral contraceptive administration (OCP) in this population.
    Summary · context
    Administration of rhIGF-I was placebo controlled and blinded to subjects.

    In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).

  2. 06HumanNot a test of IGF-1 (mecasermin) aloneRandomized controlled trialEfficacy outcome

    In osteopenic women with anorexia nervosa, spinal bone density change was 1.8% with rhIGF-I plus OCP versus 0.3% with rhIGF-I alone.

    In plain wordsIn women with anorexia nervosa, spinal bone density change was greater with rhIGF-I plus oral contraceptive than rhIGF-I alone.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseCombined treatment spinal bone density versus rhIGF-I alone
    Study

    n: not reported in source

    Comparator
    rhIGF-I alone
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Spinal bone density change, mean (+/- 0.8%)
    1.8%
    rhIGF-I plus OCP
    Spinal bone density change, mean (+/- 0.6%)
    0.3%
    rhIGF-I alone

    Source sentences

    Summary
    However, bone density increased to the greatest extent in the combined treatment group (rhIGF-I and OCP), compared with control patients receiving no active therapy (1.8% +/- 0.8% vs. 0.3% +/- 0.6% vs. -0.2% +/- 0.8% vs. -1.0% +/- 1.3%, rhIGF-I and OCP vs. rhIGF-I alone vs. OCP alone vs. no active t…
    2 context sentences
    Summary · context
    We tested the hypothesis that recombinant human IGF-I (rhIGF-I) would increase bone density in women with anorexia nervosa and furthermore assessed the effects of combined rhIGF-I and oral contraceptive administration (OCP) in this population.
    Summary · context
    Administration of rhIGF-I was placebo controlled and blinded to subjects.

    In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.